Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

This study has been completed.
Information provided by (Responsible Party):
Merck KGaA Identifier:
First received: August 19, 2008
Last updated: March 10, 2014
Last verified: March 2014

This is an international, multicenter study involving children treated with Saizen®, a growth hormone, who will be trained to use easypod, a new electronic injector and will complete a questionnaire after 12 week of use.

Both children naïve to growth hormone and dissatisfied with their current injection device will be recruited.

Growth Hormone Deficiency
Turner Syndrome
Chronic Renal Failure
Small for Gestational Age

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector When Administering Saizen® Growth Hormone to Children With Growth Disorders

Resource links provided by NLM:

Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • To assess children's compliance with the Saizen®, growth hormone treatment, following introduction of the new easypodTM self-injector, while comparing newly treated and previously treated children. [ Time Frame: week 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the acceptability of the new Easypod™ electronic injector for children following a growth hormone treatment regimen. [ Time Frame: week 12 ] [ Designated as safety issue: No ]

Enrollment: 834
Study Start Date: June 2007
Study Completion Date: June 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)

Detailed Description:

An international, multicenter cross-sectional study (Observatoire des pratiques médicales®) involving a cohort of children treated with Saizen®, a growth hormone.

The study does not require any changes to the usual medical management of these patients and should not be considered detrimental to their physical or psychological integrity. No specific procedures or examinations will be requested, nor does the protocol require any particular treatment or follow-up visits.


Ages Eligible for Study:   2 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Overall, 834 children using the electronic auto-injector were recruited. Of these, 824 children were included in the evaluable population. Of the 824 evaluable children, 601 were treatment-naïve and 223 were treatment-experienced.


Inclusion Criteria:

  • Already treated patients who are dissatisfied with their current self-injection device, or naïve pediatric patients, in cases for which this indication is validated (growth hormone deficiency, Turner's syndrome, chronic renal failure, small-for-gestational age [SGA] patients, based on RCP)

Exclusion Criteria:

  • Cases in which Saizen® is contra-indicated (based on local RCP)
  • Children returning for consultation, who have not brought back their Easypod™ electronic self-injector.
  • Children who are participating in a therapeutic trial, or who have done so in the 3-month period preceding their recruitment into this observational study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00738205

Sponsors and Collaborators
Merck KGaA
Study Director: Clément Olivier, MD, LMCC Merck Serono S.A., Geneva
  More Information

Responsible Party: Merck KGaA Identifier: NCT00738205     History of Changes
Other Study ID Numbers: Easypod
Study First Received: August 19, 2008
Last Updated: March 10, 2014
Health Authority: Italy: Ethics Committee

Keywords provided by Merck KGaA:
Electronic device
Growth hormone treatment

Additional relevant MeSH terms:
Dwarfism, Pituitary
Gonadal Dysgenesis
Kidney Failure, Chronic
Primary Ovarian Insufficiency
Renal Insufficiency
Turner Syndrome
Adnexal Diseases
Bone Diseases
Bone Diseases, Developmental
Bone Diseases, Endocrine
Brain Diseases
Cardiovascular Abnormalities
Cardiovascular Diseases
Central Nervous System Diseases
Chromosome Disorders
Congenital Abnormalities
Disorders of Sex Development
Endocrine System Diseases
Genetic Diseases, Inborn
Genital Diseases, Female
Gonadal Disorders
Heart Defects, Congenital
Heart Diseases
Hypothalamic Diseases
Kidney Diseases
Musculoskeletal Diseases
Nervous System Diseases
Ovarian Diseases processed this record on November 27, 2014